Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

UCB, Cancer Research UK expand strategic alliance to advance novel oncology therapies with milestone and royalty payments
Research collaboration, oncology, antibody, milestone payments, royalties, co-development - Read more

AstraZeneca, Immunai expand AI oncology pact through 2027, up to $37.5M deal
Research collaboration, oncology, AI/ML, milestone payments, drug discovery - Read more

Halozyme Therapeutics, GSK collaborate on subcutaneous oncology ADC formulations using ENHANZE technology
Licensing deal, oncology, antibody drug conjugates, drug delivery, milestone payments, royalties - Read more

Bristol Myers Squibb licenses Lonza's SYNtecan ADC linker-payload platform for undisclosed target, milestones and royalties eligible
Licensing deal, antibody-drug conjugate, drug discovery, milestone payments, royalties - Read more

Avalo Therapeutics' (abdakibart) meets Ph2 primary endpoint in moderate-to-severe hidradenitis suppurativa, advancing toward registrational study
Antibody, autoimmune, monoclonal antibody, hidradenitis suppurativa, IL-1β, skin disease - Read more

AIM ImmunoTech's Ampligen (rintatolimod) achieves 50% objective response rate in Ph2 recurrent ovarian cancer trial
Small molecule, cancer, combination therapy, ovarian cancer, checkpoint inhibitor, immunotherapy - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Banyan BioInnovations launches with $100M and Icon partnership to develop clinical-stage NewCo companies
Co-development, clinical-stage, CRO partnership, equity investment, R&D, commercialization - Read more

Blackstone invests $250M in Anagram Therapeutics to develop cystic fibrosis EPI therapy
Cystic fibrosis, rare disease, enzyme replacement therapy, oral therapy, clinical-stage - Read more

Viridian Therapeutics raises $350M via convertible notes and equity offerings for autoimmune and rare diseases
Autoimmune, rare disease, clinical-stage, small molecule - Read more

ParcelBio raises $13M seed round to advance APEXm mRNA expression platform
mRNA platform, Cell therapy, Autoimmune, Oncology, Preclinical, Platform technology - Read more

Odyssey Therapeutics prices upsized $304M IPO for autoimmune and inflammatory disease medicines
Autoimmune, inflammatory disease, clinical-stage, small molecule - Read more

Cartography Biosciences receives undisclosed Samsung Ventures investment for oncology pipeline advancement
Oncology, antibody, AI-driven, drug discovery, clinical-stage - Read more

Cytokinetics prices upsized $700M public offering of common stock
Cardiovascular, small molecule, clinical-stage - Read more

Roche to acquire PathAI for up to $1.05B to expand digital pathology and AI diagnostics globally
Digital pathology, oncology, major transaction, strategic - Read more

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B, expanding into U.S. rare neurological drug market
Small molecule, rare disease, neurological, major transaction, strategic - Read more

Pierre Fabre, FDA align on Ebvallo BLA resubmission path using updated ALLELE study data
Allogeneic T-cell therapy, rare disease, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

BeOne Medicines halts Ph2 trial of (BGB-45035), IRAK4 degrader, in rheumatoid arthritis amid emerging new data
Small molecule, cancer, autoimmune, EGFR inhibitor, KRAS inhibitor, CDK2 inhibitor - Read more

Entrada Therapeutics' (ENTR-601-44) Ph1/2 dystrophin data falls below expectations in Duchenne muscular dystrophy trial
Oligonucleotide, neurological, antisense oligonucleotide, Duchenne muscular dystrophy, exon skipping, dystrophin - Read more

enGene Therapeutics' (detalimogene voraplasmid) Ph2 data disappoints in BCG-unresponsive non-muscle-invasive bladder cancer with waning durability
Gene therapy, cancer, bladder cancer, non-muscle-invasive bladder cancer, BCG-unresponsive, intravesical delivery - Read more

Sarepta Therapeutics shares tumble 10% as Elevidys gene therapy sales continue quarterly decline
Gene therapy, rare disease, financial, competitive, siRNA - Read more

FDA rebukes Alnylam over misleading Amvuttra website efficacy claims using open-label data
RNAi therapy, cardiovascular, regulatory, competitive - Read more

Ascendis Pharma axes IL-2 cancer program, refocusing pipeline on rare endocrinology diseases
IL-2 cytokine, oncology, strategic, pipeline discontinuation - Read more

Gilead wipes out 87% of Arcellx workforce, laying off 192 employees after $7.8B acquisition
CAR-T, multiple myeloma, major transaction, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here